Mochi Health vs Hims & Hers

Mochi Health vs Hims & Hers at every dose

A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.

What differs beyond price

Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.

Which one, for whom

If you want the lowest total cost: neither can be ranked on cost until both publish a price.

If you want budget certainty: Mochi Health, which holds one price at every strength.

If you want to verify the supply chain: neither names a dispensing pharmacy in a way we could verify — ask both directly.

If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.

Switching between them

Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 2.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

Mochi Health charges a mandatory membership of $79 a month on top of medication. Hims & Hers charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

Mochi Health: video, labs optional, dietitian access. Hims & Hers: async, labs optional, included.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

Mochi Health: owned facility. Hims & Hers: brand only since Mar 2026.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

What can still be decided here

Without a price on both sides this cannot be settled on cost, so it has to be settled on everything else — and everything else is frequently the better basis anyway.

Mochi Health publishes: visit model video, laboratory requirement optional, pharmacy owned facility, cancellation membership recurring. Hims & Hers publishes: visit model async, laboratory requirement optional, pharmacy brand only since Mar 2026, cancellation membership recurring.

A programme that publishes four of those and one that publishes none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 10 mg including every fee, in writing, and see which answers.

How much mochi health and hims & hers should weigh

Less than the pharmacy question and more than the entry price. That ordering is unusual in published guidance, which typically inverts it, and it follows from what actually goes wrong: interrupted supply and unverifiable sourcing cost more than a modest price difference ever saves.

A useful test is whether a fact would change your decision if it were twice as bad. Double the price gap between the cheapest and second-cheapest verified routes and most people still choose on disclosure. Double the uncertainty about who compounded the vial and nobody should.

What a well-run programme publishes

The figure at 10 mg rather than at initiation. The pharmacy, by name. The prescriber or medical director. The cancellation notice period. And an unambiguous statement that a compounded preparation is not FDA-approved and is not reviewed for safety, effectiveness or quality before marketing.

Across the 17 priced programmes, the ones doing all of that span roughly the same price range as the ones doing none. Transparency here is a choice rather than a cost, which makes its absence informative rather than neutral.

The next step that actually moves things

Price your own course rather than reading someone else's ranking. Take the dose you expect to maintain, add every recurring fee, multiply by twelve, then ask whether you could sustain it for three years — the horizon the withdrawal evidence implies rather than the twelve months every comparison uses.

If the answer is no even at $215 a month, the useful move is checking coverage under a different indication rather than hunting a lower cash price. The cash market has a floor, and figures materially below it usually indicate one of four specific distortions.

Why this comparison cannot be settled on price

Only Mochi Health publishes a price we could capture, at about $3,336 for a first year at a maintenance dose. The other does not. A comparison that filled that gap with an estimate would be inventing the only number that matters.

What can be compared is what each discloses before you pay, and that is frequently the more useful comparison anyway. A programme that names its pharmacy, states its cancellation terms and publishes a price at every dose has told you how it will behave when something goes wrong.

What to do instead

Ask both for the total at 10 mg including every fee, in writing, and compare the replies against the programmes that already publish. If one answers in a sentence and the other does not answer at all, you have your comparison.

Why we publish the page anyway

Because the absence is the finding. Someone searching for this pairing deserves to know that one side cannot be priced, rather than being shown a fabricated number or no page at all.

Fee structure, side by side

Mochi Health charges a mandatory membership of $79 a month on top of medication. Hims & Hers charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

Mochi Health: video, labs optional, dietitian access. Hims & Hers: async, labs optional, included.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

Mochi Health: owned facility. Hims & Hers: brand only since Mar 2026.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

What can still be decided here

Without a price on both sides this cannot be settled on cost, so it has to be settled on everything else — and everything else is frequently the better basis anyway.

Mochi Health publishes: visit model video, laboratory requirement optional, pharmacy owned facility, cancellation membership recurring. Hims & Hers publishes: visit model async, laboratory requirement optional, pharmacy brand only since Mar 2026, cancellation membership recurring.

A programme that publishes four of those and one that publishes none are not equally knowable, and that asymmetry is a finding rather than a gap in our research. Ask both for the total at 10 mg including every fee, in writing, and see which answers.

How much mochi health and hims & hers should weigh

Less than the pharmacy question and more than the entry price. That ordering is unusual in published guidance, which typically inverts it, and it follows from what actually goes wrong: interrupted supply and unverifiable sourcing cost more than a modest price difference ever saves.

A useful test is whether a fact would change your decision if it were twice as bad. Double the price gap between the cheapest and second-cheapest verified routes and most people still choose on disclosure. Double the uncertainty about who compounded the vial and nobody should.

What a well-run programme publishes

The figure at 10 mg rather than at initiation. The pharmacy, by name. The prescriber or medical director. The cancellation notice period. And an unambiguous statement that a compounded preparation is not FDA-approved and is not reviewed for safety, effectiveness or quality before marketing.

Across the 17 priced programmes, the ones doing all of that span roughly the same price range as the ones doing none. Transparency here is a choice rather than a cost, which makes its absence informative rather than neutral.

The next step that actually moves things

Price your own course rather than reading someone else's ranking. Take the dose you expect to maintain, add every recurring fee, multiply by twelve, then ask whether you could sustain it for three years — the horizon the withdrawal evidence implies rather than the twelve months every comparison uses.

If the answer is no even at $215 a month, the useful move is checking coverage under a different indication rather than hunting a lower cash price. The cash market has a floor, and figures materially below it usually indicate one of four specific distortions.